We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » COVID-19 Monoclonal Antibodies Still Aren’t Widely Used, but New EUA Could Improve Utilization
COVID-19 Monoclonal Antibodies Still Aren’t Widely Used, but New EUA Could Improve Utilization
The U.S. has secured a hefty supply of COVID-19 monoclonal antibodies, but challenges in administering the potentially game-changing treatments and skepticism around their efficacy have contributed to their minimal use. Now, a newly issued Emergency Use Authorization (EUA) for an antibody combo could inspire greater assurance in the drugs as potential treatments for preventing hospitalization.